Ranbaxy Laboratories, India's first multinational pharmaceutical company, plans to supply medicines to Japan from its Indian facilities, according to sources.
Ranbaxy is yet to get approvals from the Japanese regulatory agency, but is reportedly in advanced talks with Japan's Ministry of Health, Labour and Welfare.
In 2008, Japan's No. 3 drugmaker, Daiichi Sankyo, bought 63.9 percent of Ranbaxy for $4.2 billion from the controlling shareholder group. Daiichi Sankyo Espha Co Ltd will be the vehicle to introduce generic products in Japan, through a joint team set up for development, sales and distribution.